loading...| Preferred Name |
Naloxegol |
|
| Synonyms |
|
|
| Definitions |
A pegylated form of naloxone, a peripherally-acting mu-opioid receptor antagonist, that can be used to reduce opioid-induced symptoms. Upon administration, naloxegol binds to and blocks mu-opioid receptors in the peripheral nervous system. This prevents peripheral opioid receptor activation and abrogates opioid-induced side effects, such as opioid-induced constipation (OIC). Pegylation of naloxone reduces permeability across the blood-brain barrier (BBB) and prevents this agent from interfering with the analgesic activity of opioid receptor agonists. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C97506 |
|
| CAS_Registry |
854601-70-0 |
|
| code |
C97506 |
|
| Contributing_Source |
FDA |
|
| definition |
A pegylated form of naloxone, a peripherally-acting mu-opioid receptor antagonist, that can be used to reduce opioid-induced symptoms. Upon administration, naloxegol binds to and blocks mu-opioid receptors in the peripheral nervous system. This prevents peripheral opioid receptor activation and abrogates opioid-induced side effects, such as opioid-induced constipation (OIC). Pegylation of naloxone reduces permeability across the blood-brain barrier (BBB) and prevents this agent from interfering with the analgesic activity of opioid receptor agonists. |
|
| FDA_UNII_Code |
44T7335BKE |
|
| Has_Salt_Form | ||
| in_subset | ||
| label |
Naloxegol |
|
| NCI_Drug_Dictionary_ID |
703418 |
|
| PDQ_Closed_Trial_Search_ID |
703418 |
|
| PDQ_Open_Trial_Search_ID |
703418 |
|
| Preferred_Name |
Naloxegol |
|
| prefixIRI |
NCIT:C97506 |
|
| prefLabel |
Naloxegol |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C3700399 |
|
| subClassOf |